W33.F BioVersys AG

Healthcare Biotechnology Frankfurt Exchange
24.20 EUR
Close of Nov 12, 2026
23.00 33.00
Market cap
EUR 142M
P/E
-
P/B
2.93x
ROE
-36.5%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is W33.F undervalued?

Graham number

The Graham number of BioVersys AG cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

BioVersys AG fundamental analysis

No fundamental analysis for BioVersys AG yet.

BioVersys AG stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About BioVersys AG

BioVersys AG researches and develops antimicrobial drugs for bacterial infections. It develops BV100 that is in Phase 3 clinical trial for carbapenem-resistant Acinetobacter baumannii lung and bloodstream infections. The company is also developing Alpibectir, which is in Phase 2 clinical trial for the treatment of pulmonary and meningeal tuberculosis; BV200 to treat patients with Gram-positive S. aureus; and BV500 for non-tuberculous mycobacteria infections. It has a researc…

Full company profile